Theraclion Growth Up in S1 2025
THERACLION (ISIN: FR0010120402; Mnemo: ALTHE), an innovative company developing Sonovein®, a robotic platform for non-invasive High-Intensity Focused Ultrasound (HIFU) varicose vein treatment, reviews its business for S1 2025.
Sales of consumables (recurring revenue) up 30% compared to 2024
New treatment centers opened in Bulgaria and Spain
Appointment of a new business manager and acceleration of commercial activities
On-schedule completion of the follow-up period for the pivotal FDA clinical trial
Martin Deterre, CEO of Theraclion, states: "In early 2025, Theraclion stepped up Sonovein's activity. In June, the final 12-month follow-ups for patients in the pivotal FDA-approved clinical trial were completed on-schedule. We are now awaiting the final results, which we expect to publish in September. Theraclion has also entered a business development phase: building a sales and marketing team, opening two new Sonovein treatment centers, and achieving significant growth in recurring revenue — all of which promise the achievement of our ambitious goals."
Commercial activity acceleration
As part of its business development, Theraclion is actively building its sales and marketing team. In May 2025, Thibault Le Normand joined the company as Chief Business Officer to boost sales in the Middle East and product placements (PPUs) of Sonovein in Europe. With over a decade of experience in international development of medical devices, Thibault Le Normand brings valuable expertise to this strategic growth phase.
At the same time, the technological credibility and clinical maturity of Sonovein have been further demonstrated by the publication of new scientific articles as well as by over a dozen presentations at major international congresses by renowned physicians using the device. Sonovein's international profile has also increased through Theraclion's participation in congresses, such as Vein in Venice (April, Venice), Venous Symposium (May, New York), and the European Venous Forum (June, Krakow). This outreach effort was supported by the launch of a new product identity and a new website, www.sonovein.com, giving Sonovein a new brand image that reflects innovation, clinical excellence, and ambition.
In addition, two new product placement (PPU) contracts for Sonovein have been signed in Bulgaria and Spain, stepping up Theraclion's presence in Europe and expanding the installed base of the technology.
Revenue for S1 2025
Theraclion's revenue for S1 2025 was €835K, up 89% compared to 2024 (€442K) (prior to the non-recurring adjustment of €680K related to the cancellation of Echopulse system sales in 2024).
Consumables, which include recurring revenues from PPUs, was up 30% compared to S1 2024. Service revenues were up 232% over the same period. This strong momentum is a key indicator of increasing use of Sonovein by treatment centers and reflects the technology's sustained traction in the field.
Combined, consumables and services — representing recurring revenue — was up 57% compared to 2024.
Progress of the pivotal FDA clinical trial
In the USA, the pivotal FDA-approved study for SONOVEIN® reached a major milestone in June 2025 with the on-schedule completion of the 12-month post-treatment patient follow-ups. Data analysis is currently underway, with results expected in September.
Submission of the marketing authorization application to the FDA is planned for Fall 2025, with potential approval estimated for Q2 2026, subject to the FDA's processing time. This progress marks a critical strategic milestone in the work to access the world's largest market for venous disease treatment.
Next financial publication:
Theraclion will publish its interim financial results on October 29, 2025.
About Theraclion
Theraclion is a French MedTech company committed to developing a non-invasive alternative to surgery through the innovative use of focused ultrasound.
High Intensity Focused Ultrasound (HIFU) does not require incisions or an operating room, leaves no scars, and patients can immediately resume their routines. HIFU treatment concentrates therapeutic ultrasounds on an internal focal point from outside the body.
Theraclion is developing SONOVEIN®, a CE-marked, a robotic platform for HIFU varicose vein treatment, which could replace millions of surgical procedures every year. In the USA, SONOVEIN® is an investigational device limited to investigational use; it is not available for sale in the USA.
Based in Malakoff (Paris), the Theraclion team comprises some 30 people, most of them involved in technological and clinical development.
Theraclion is listed on Euronext Growth Paris
Eligible for the PEA-PME scheme
Mnemonic: ALTHE - ISIN code: FR0010120402
LEI: 9695007X7HA7A1GCYD29
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
Recall issued over energy drinks mistakenly containing vodka
MODESTO, Calif. (AP) — Energy drinks that mistakenly contain vodka are being recalled in half a dozen states. High Noon is recalling two production lots of High Noon Beach Variety packs because some packs include cans containing vodka that were mislabeled as Celsius Astro Vibe Energy Drink, according to a U.S. Food and Drug Administration recall notice Wednesday. The cans contain vodka seltzer and were mislabeled as 'sparkling blue razz'-flavored Celsius Astro Vibe energy drinks, the notice said. Consumption of the liquid in the cans will result in 'unintentional alcohol ingestion,' the company said. The packs were distributed to retailers in Florida, New York, Ohio, South Carolina, Virginia and Wisconsin. The recall was initiated after the company discovered that a shared packaging supplier mistakenly shipped empty Celsius energy drink cans to High Noon. No illnesses or adverse events have been reported related to the labeling error, according to the company. Consumers who purchased the beverages with the impacted codes found in the recall notice should dispose of it, the notice said. Consumers are also encouraged to make sure any Sparkling Blue Razz Celsius Astro Vibe energy drinks do not contain the specific lot codes in the notice before drinking them. The Associated Press Sign in to access your portfolio
Wall Street Journal
21 minutes ago
- Wall Street Journal
WSJ Opinion: The FDA's Gene-Therapy Reversal and the Exit of Vinay Prasad
A top official at the Food and Drug Administration steps down after the agency changes course on a treatment for Duchenne muscular dystrophy. What does this say about the Trump Administration's approach toward drug innovation?
Business Wire
22 minutes ago
- Business Wire
NewMarket Corporation Reports Second Quarter and First Half 2025 Results
RICHMOND, Va.--(BUSINESS WIRE)--NewMarket Corporation (NYSE:NEU) Chairman and Chief Executive Officer, Thomas E. Gottwald, released the following earnings report of the Company's operations for the second quarter and first half of 2025. Net income for the second quarter of 2025 was $111.2 million, or $11.84 per share, compared to net income of $111.6 million, or $11.63 per share, for the same period last year. For the first half of 2025, net income was $237.2 million, or $25.11 per share, compared to $219.4 million, or $22.87 per share, for the same period in 2024. Petroleum additives sales for the second quarter of 2025 were $653.9 million, compared to $669.8 million for the same period in 2024. Petroleum additives operating profit for the second quarter of 2025 was $139.8 million, compared to $147.8 million for the second quarter of 2024. The decrease in petroleum additives operating profit was primarily driven by a 2.5% decline in shipments between quarterly periods and an increase in technology investments, slightly offset by favorable product mix. The decline in shipments was mainly driven by lubricant additives shipments, partially offset by a slight increase in fuel additives shipments. Petroleum additives sales were $1.3 billion for the first half of 2025 and the first half of 2024. Petroleum additives operating profit for the first half of 2025 was $281.9 million, compared to $298.7 million in the same period last year. The drivers for the decrease in operating profit between these periods were consistent with those affecting the second quarter comparison discussed above. Shipments decreased 4.9% when comparing the first half of 2025 with the same period in 2024, with decreases in both lubricant additives and fuel additives shipments. Specialty materials sales were $42.0 million for the second quarter of 2025, compared to $38.0 million for the second quarter of 2024. Specialty materials operating profit was $10.5 million for the second quarter of 2025, compared to operating profit of $5.0 million for the second quarter of 2024. The increase in specialty materials operating profit was primarily driven by increased volumes. As previously stated, we will see substantial variation in quarterly results for the specialty materials segment on an ongoing basis due to the nature of its business. Specialty materials sales were $95.8 million for the first half of 2025, compared to $55.1 million for the first half of 2024. Specialty materials operating profit for the first half of 2025 was $33.7 million, compared to slightly above breakeven in the same period last year. Specialty materials sales and operating profit for the first half of 2024 reflect financial results since the acquisition of American Pacific Corporation (AMPAC) on January 16, 2024. Our operations generated solid cash flows during the first half of 2025. We repurchased common stock for $77.2 million, including $20.2 million of repurchases in the second quarter, paid dividends of $51.9 million, and funded capital expenditures of $29.3 million in the first half of 2025. Additionally, we reduced our Net Debt by $122.2 million during the first half of 2025, driving our Net Debt to EBITDA ratio down to 1.0 as of June 30, 2025. We are pleased with the strong performance of our business during the first half of 2025 and continue to see favorable results from our ongoing efficiency initiatives. Investing in technology to meet customer needs, enhancing our operational efficiency, and improving our portfolio profitability will remain priorities throughout 2025. We continue to monitor the uncertain macroeconomic environment, particularly the changes in international trade relations and tariffs, and assess the potential impacts to our operations. Our dedicated team makes decisions to promote long-term value for our shareholders and customers, and remains focused on our long-term objectives. We believe the fundamentals of how we run our business - a long-term view, safety-first culture, customer-focused solutions, technology-driven product offerings, and world-class supply chain capability - will continue to be beneficial for all our stakeholders. Sincerely, Thomas E. Gottwald The petroleum additives segment consists of the North America (the United States and Canada), Latin America (Mexico, Central America, and South America), Asia Pacific, and Europe/Middle East/Africa/India (Europe or EMEAI) regions. The specialty materials segment, which consists of the AMPAC business, operates primarily in North America. The Company has disclosed the non-GAAP financial measures EBITDA, Net Debt, and Net Debt to EBITDA, as well as the related calculations in the schedules included with this earnings release. EBITDA is defined as income from continuing operations before the deduction of interest and financing expenses, income taxes, depreciation (on property, plant, and equipment) and amortization (on intangibles and lease right-of-use assets). Net Debt is defined as long-term debt, including current maturities, less cash and cash equivalents. Net Debt to EBITDA is defined as Net Debt divided by EBITDA for the rolling four quarters ended as of the specified date. The Company believes that even though these items are not required by or presented in accordance with United States generally accepted accounting principles (GAAP), these additional measures enhance understanding of the Company's performance and period to period comparability. The Company believes that these items should not be considered an alternative to our results determined under GAAP. As a reminder, a conference call and webcast is scheduled for 3:00 p.m. ET on Thursday, July 31, 2025, to review second quarter 2025 financial results. You can access the conference call live by dialing 1-888-506-0062 (domestic) or 1-973-528-0011 (international) and requesting the NewMarket conference call. To avoid delays, callers should dial in five minutes early. A teleconference replay of the call will be available until Thursday, August 7, 2025, at 3:00 p.m. ET by dialing 1-877-481-4010 (domestic) or 1-919-882-2331 (international). The replay passcode number is 52660. The call will also be broadcast via the internet and can be accessed through the Company's website at or A webcast replay will be available for 30 days. NewMarket Corporation is a holding company operating through its subsidiaries, Afton Chemical Corporation (Afton), Ethyl Corporation (Ethyl), and American Pacific Corporation (AMPAC). The Afton and Ethyl companies develop, manufacture, blend, and deliver chemical additives that enhance the performance of petroleum products. AMPAC is a manufacturer of specialty materials primarily used in solid rocket motors for the aerospace and defense industries. The NewMarket family of companies has a long-term commitment to its people, to safety, to providing innovative solutions for its customers, and to making the world a better place. Some of the information contained in this press release constitutes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Although NewMarket's management believes its expectations are based on reasonable assumptions within the bounds of its knowledge of its business and operations, there can be no assurance that actual results will not differ materially from expectations. Factors that could cause actual results to differ materially from expectations include, but are not limited to, the availability of raw materials and distribution systems; disruptions at production facilities, including single-sourced facilities; hazards common to chemical businesses; the ability to respond effectively to technological changes in our industries; failure to protect our intellectual property rights; sudden, sharp, or prolonged raw material price increases; competition from other manufacturers; current and future governmental regulations; the loss of significant customers; termination or changes to contracts with contractors and subcontractors of the U.S. government or directly with the U.S. government; failure to attract and retain a highly-qualified workforce; an information technology system failure or security breach; the occurrence or threat of extraordinary events, including natural disasters, terrorist attacks, wars and health-related epidemics; risks related to operating outside of the United States, including tariffs and trade policy; political, economic, and regulatory factors concerning our products; the impact of substantial indebtedness on our operational and financial flexibility; the impact of fluctuations in foreign exchange rates; resolution of environmental liabilities or legal proceedings; limitation of our insurance coverage; our inability to realize expected benefits from investment in our infrastructure or from acquisitions, or our inability to successfully integrate acquisitions into our business; the underperformance of our pension assets resulting in additional cash contributions to our pension plans; and other factors detailed from time to time in the reports that NewMarket files with the Securities and Exchange Commission, including the risk factors in Part I, Item 1A. 'Risk Factors' of our Annual Report on Form 10-K for the year ended December 31, 2024, which is available to shareholders at You should keep in mind that any forward-looking statement made by NewMarket in the foregoing discussion speaks only as of the date on which such forward-looking statement is made. New risks and uncertainties arise from time to time, and it is impossible for us to predict these events or how they may affect us. We have no duty to, and do not intend to, update or revise the forward-looking statements in this discussion after the date hereof, except as may be required by law. In light of these risks and uncertainties, you should keep in mind that the events described in any forward-looking statement made in this discussion, or elsewhere, might not occur. NEWMARKET CORPORATION AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF INCOME (In thousands, except per-share amounts, unaudited) Second Quarter Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Net sales $ 698,509 $ 710,228 $ 1,399,455 $ 1,406,964 Cost of goods sold 477,555 491,773 942,478 972,144 Gross profit 220,954 218,455 456,977 434,820 Selling, general, and administrative expenses 45,428 42,840 88,406 87,205 Research, development, and testing expenses 32,374 28,663 65,550 59,863 Operating profit 143,152 146,952 303,021 287,752 Interest and financing expenses, net 10,735 15,910 21,435 31,564 Other income (expense), net 15,271 11,952 30,215 24,499 Income before income tax expense 147,688 142,994 311,801 280,687 Income tax expense 36,444 31,374 74,608 61,335 Net income $ 111,244 $ 111,620 $ 237,193 $ 219,352 Earnings per share - basic and diluted $ 11.84 $ 11.63 $ 25.11 $ 22.87 Cash dividends declared per share $ 2.75 $ 2.50 $ 5.50 $ 5.00 Expand NEWMARKET CORPORATION AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS (In thousands, except share amounts, unaudited) June 30, 2025 December 31, 2024 ASSETS Current assets: Cash and cash equivalents $ 70,257 $ 77,476 Trade and other accounts receivable, less allowance for credit losses 453,709 395,450 Inventories 494,849 505,426 Prepaid expenses and other current assets 49,001 51,203 Total current assets 1,067,816 1,029,555 Property, plant, and equipment, net 739,182 735,361 Intangibles (net of amortization) and goodwill 737,873 750,424 Prepaid pension cost 518,818 490,418 Operating lease right-of-use assets, net 76,247 71,253 Deferred charges and other assets 54,593 52,530 Total assets $ 3,194,529 $ 3,129,541 LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities: Accounts payable $ 260,486 $ 225,874 Accrued expenses 77,568 89,277 Dividends payable 21,460 22,037 Income taxes payable 18,647 15,798 Operating lease liabilities 17,170 15,337 Other current liabilities 6,741 6,155 Total current liabilities 402,072 374,478 Long-term debt 841,829 971,281 Operating lease liabilities - noncurrent 59,377 54,754 Other noncurrent liabilities 279,528 267,445 Total liabilities 1,582,806 1,667,958 Shareholders' equity: Common stock and paid-in capital (with no par value; issued and outstanding shares - 9,396,621 at June 30, 2025 and 9,524,789 at December 31, 2024) 515 0 Accumulated other comprehensive income 69,702 32,870 Retained earnings 1,541,506 1,428,713 Total shareholders' equity 1,611,723 1,461,583 Total liabilities and shareholders' equity $ 3,194,529 $ 3,129,541 Expand NEWMARKET CORPORATION AND SUBSIDIARIES SELECTED CONSOLIDATED CASH FLOW DATA (In thousands, unaudited) Six Months Ended June 30, 2025 2024 Net income $ 237,193 $ 219,352 Depreciation and amortization 57,270 55,130 Cash pension and postretirement contributions (4,871 ) (5,781 ) Working capital changes (828 ) (40,696 ) Deferred income tax expense (benefit) 4,604 (7,461 ) Capital expenditures (29,295 ) (28,533 ) Acquisition of business, net of cash acquired 0 (681,479 ) Net (repayments) borrowings under revolving credit facility (30,000 ) 279,000 Principal payment on 3.78% senior note (50,000 ) 0 (Payment) proceeds on term loan (50,000 ) 250,000 Dividends paid (51,898 ) (47,972 ) Repurchases of common stock (77,218 ) 0 Debt issuance costs 0 (2,251 ) All other (12,176 ) (13,613 ) Decrease in cash and cash equivalents $ (7,219 ) $ (24,304 ) Expand
